- Stocks
- Healthcare
- NYSE: OGN

Price (delayed)

$18.5

Market cap

$4.73B

P/E Ratio

8.04

Dividend/share

$1.12

EPS

$2.3

Enterprise value

$12.97B

The equity is up by 45% YoY but it is down by 6% QoQ

The company's EPS fell by 42% YoY and by 22% QoQ

Organon's net income has decreased by 42% YoY and by 22% from the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - General

What are the main financial stats of OGN

Market
Valuations
Earnings

Shares outstanding

255.61M

Market cap

$4.73B

Enterprise value

$12.97B

Price to book (P/B)

N/A

Price to sales (P/S)

0.77

EV/EBIT

10.83

EV/EBITDA

9.1

EV/Sales

2.11

Revenue

$6.15B

EBIT

$1.2B

EBITDA

$1.43B

Free cash flow

$439M

Per share
Balance sheet
Liquidity

EPS

$2.3

Free cash flow per share

$1.72

Book value per share

-$2.3

Revenue per share

$24.06

TBVPS

$22.88

Total assets

$11.01B

Total liabilities

$11.6B

Debt

$8.65B

Equity

-$589M

Working capital

$1.56B

Debt to equity

-14.69

Current ratio

1.63

Quick ratio

0.83

Net debt/EBITDA

5.78

Margins
Efficiency
Dividend

EBITDA margin

23.2%

Gross margin

60.6%

Net margin

9.5%

Operating margin

20.4%

Return on assets

5.4%

Return on equity

N/A

Return on invested capital

10.4%

Return on capital employed

14%

Return on sales

19.5%

Dividend yield

6.05%

DPS

$1.12

Payout ratio

48.7%

How has the Organon stock price performed over time

Intraday

-0.27%

1 week

-1.12%

1 month

13.71%

1 year

-30.58%

YTD

28.29%

QTD

28.29%

How have Organon's revenue and profit performed over time

Revenue

$6.15B

Gross profit

$3.72B

Operating income

$1.25B

Net income

$585M

Gross margin

60.6%

Net margin

9.5%

Organon's net income has decreased by 42% YoY and by 22% from the previous quarter

Organon's net margin has decreased by 41% YoY and by 22% from the previous quarter

The company's operating income fell by 23% YoY and by 12% QoQ

OGN's operating margin is down by 21% year-on-year and by 11% since the previous quarter

What is Organon's growth rate over time

What is Organon stock price valuation

P/E

8.04

P/B

N/A

P/S

0.77

EV/EBIT

10.83

EV/EBITDA

9.1

EV/Sales

2.11

The company's EPS fell by 42% YoY and by 22% QoQ

The price to earnings (P/E) is 6% more than the last 4 quarters average of 7.6

The equity is up by 45% YoY but it is down by 6% QoQ

The price to sales (P/S) is 14% lower than the last 4 quarters average of 0.9

The revenue has declined by 2.3% year-on-year

How efficient is Organon business performance

The ROA has declined by 44% year-on-year and by 23% since the previous quarter

The return on invested capital has declined by 29% year-on-year and by 13% since the previous quarter

The company's return on sales fell by 26% YoY and by 13% QoQ

What is OGN's dividend history

DPS

$1.12

Dividend yield

6.05%

Payout ratio

48.7%

Recent dividends

How did Organon financials performed over time

OGN's total assets is 5% less than its total liabilities

OGN's total assets is up by 6% YoY

OGN's current ratio is up by 6% year-on-year

The debt to equity has plunged by 80% YoY but it has grown by 7% from the previous quarter

The equity is up by 45% YoY but it is down by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.